

SCAAR

Real-life clinical outcomes with the use of Orsiro™ in Sweden: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

Conclusions

- In this large, nationwide, retrospective analysis Orsiro™ is associated with a significantly lower risk of Target Lesion Revascularization (TLR) compared to other modern n-DES*.
- Orsiro™ shows numerically lower rates of In-Stent Restenosis (ISR) and definite Stent Thrombosis (ST) compared to other modern n-DES.
- These results emphasize the potential incremental clinical benefits of Orsiro™'s ultrathin strut during Percutaneous Coronary Intervention (PCI).


Study design

Nationwide, retrospective, multicentre, observational registry recording all PCI procedures in Sweden between 2011 and 2017.

Endpoints

Clinical endpoint

- All-cause Death, Myocardial Infarction (MI), Definite ST, ISR, TLR by PCI out to 2 years



PATIENT CHARACTERISTICS ¹	ORSIRO™ N=4,561	N-DES N=69,570	SMD**
Age years, (SD) [†]	67.2±11.1	67.8±10.9	0.049
Male	74.1 %	73.7 %	0.008
Diabetes	22.1 %	21.4 %	0.018
Hypertension	62.9 %	61.5 %	0.029
Previous MI	22.1 %	21.0 %	0.027
Previous PCI	17.1 %	17.8 %	0.019
Clinical indication			
Stable CAD	20.4 %	20.8 %	0.049
Unstable CAD	9.7 %	9.9 %	0.049
NSTEMI	38.7 %	39.7 %	0.049
STEMI	28.5 %	26.6 %	0.049



LESION CHARACTERISTICS ¹	ORSIRO™ N=4,561	N-DES N=69,570	SMD
B2/C	65.6 %	61.6 %	0.084
Bifurcation	19.0 %	18.7 %	0.008
3VD/LM	20.3 %	23.1 %	0.067

* n-DES: Xience Family, Resolute Family, Promus Family, Synergy, and Ultimaster >1000 implantations

** SMD: Standardized Mean Difference, value >0.1 may indicate statistically significant differences.²


[†] Data shown as mean±SD

TLR rate by PCI out to 2 years¹




vs. other
n-DES

ISR rate out to 2 years¹



Definite ST rate out to 2 years¹



Clinical outcomes out to 2 years¹

CLINICAL ENDPOINT	ADJUSTED HR (95 % CI) ORSIRO™ VS. N-DES	P-VALUE
TLR	0.75 [0.60-0.94]	0.013
All-cause Death	0.99 [0.72-1.35]	0.94
MI	1.19 [0.99-1.43]	0.06
ISR	0.81 [0.63-1.03]	0.09
DST	0.90 [0.55-1.46]	0.66

References:

- Sergio B et al. Real-life clinical outcomes with the use of an ultrathin sirolimus-eluting stent in Sweden: A report from the Swedish coronary angiography and angioplasty registry; Presented at EuroPCR 2019; May, 2019.
- Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation. 2009 May 14;38(6):1228-34.

Clinical data collected with the Orsiro DES device within the Orsiro family clinical program. Clinical data conducted with Orsiro, Orsiro Mission's predecessor device can be used to illustrate Orsiro Mission clinical outcomes.

Teleflex, the Teleflex logo, Orsiro, and Orsiro Mission are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other names are the trademarks or registered trademarks of their respective owners. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative.
Revised: 10/2025.

© 2025 Teleflex Incorporated. All rights reserved.

Distributed by:

Teleflex Headquarters International, Ireland · Teleflex Medical Europe Ltd. · IDA Business & Technology Park
Dublin Road · Athlone · Co Westmeath · Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · orders.intl@teleflex.com
United Kingdom Tel. +44 (0)14 94 53 27 61 · info.uk@teleflex.com
South Africa Tel. +27 (0)11 807 4887 · assist.africa@teleflex.com

teleflex.com

Teleflex™
Empowering the future of healthcare